Mereo BioPharma Group plc Sponsored ADR Stock

$3.73

1.06% day before yesterday

Nasdaq, Dec 27, 10:15 pm CET

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Mereo BioPharma Group plc Sponsored ADR Stock price

$3.73

+0.78 26.44% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.04 1.06%

ISIN

US5894921072

Symbol

MREO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$577.16m
Enterprise Value	$495.89m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	56.42
P/S ratio (TTM) P/S ratio	65.66
P/B ratio (TTM) P/B ratio	7.96
Revenue (TTM) Revenue	$8.79m
EBIT (operating result TTM) EBIT	$-41.30m
Free Cash Flow (TTM) Free Cash Flow	$-37.34m
Cash position	$80.52m
EPS (TTM) EPS	$-0.25
P/E forward	negative
P/S forward	31.84
EV/Sales forward	27.36
Short interest	3.98%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Mereo BioPharma Group plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Mereo BioPharma Group plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Mereo BioPharma Group plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	8.79 8.79	0% 0% 100%
- Direct Costs	3.20 3.20	0% 0% 36%
Gross Profit	5.59 5.59	0% 0% 64%
- Selling and Administrative Expenses	-	-
- Research and Development Expense	23 23	0% 0% 266%
EBITDA	-40 -40	0% 0% -460%
- Depreciation and Amortization	0.86 0.86	0% 0% 10%
EBIT (Operating Income) EBIT	-41 -41	0% 0% -470%
Net Profit	-31 -31	0% 0% -356%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mereo BioPharma Group plc Sponsored ADR Stock News

Positive

Seeking Alpha

●

about one month ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a...

Neutral

GlobeNewsWire

●

about one month ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT.

Neutral

GlobeNewsWire

●

about 2 months ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended...

More Mereo BioPharma Group plc Sponsored ADR News

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Denise Scots-Knight
Employees	33
Founded	2015
Website	www.mereobiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now